Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1993 1
1994 1
1995 2
1997 2
1998 6
1999 2
2000 3
2001 2
2002 3
2003 2
2004 3
2005 1
2006 2
2007 2
2008 4
2009 8
2010 6
2011 4
2012 2
2013 4
2014 8
2015 7
2016 10
2017 10
2018 9
2019 6
2020 8
2021 6
2022 4
2023 5
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; ECHO investigators; ECHO Investigators. Wang M, et al. J Clin Oncol. 2025 Jul 10;43(20):2276-2284. doi: 10.1200/JCO-25-00690. Epub 2025 May 1. J Clin Oncol. 2025. PMID: 40311141 Free PMC article. Clinical Trial.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: panizo c. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Bartlett NL, et al. Among authors: panizo c. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. Blood Adv. 2023. PMID: 37067952 Free PMC article.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V, Roa S, Goicoechea I, Maia C, Lasaga M, Chesi M, Bergsagel PL, Larrayoz MJ, Calasanz MJ, Campos-Sanchez E, Martinez-Cano J, Panizo C, Rodriguez-Otero P, Vicent S, Roncador G, Gonzalez P, Takahashi S, Katz SG, Walensky LD, Ruppert SM, Lasater EA, Amann M, Lozano T, Llopiz D, Sarobe P, Lasarte JJ, Planell N, Gomez-Cabrero D, Kudryashova O, Kurilovich A, Revuelta MV, Cerchietti L, Agirre X, San Miguel J, Paiva B, Prosper F, Martinez-Climent JA. Larrayoz M, et al. Among authors: panizo c. Nat Med. 2023 Mar;29(3):632-645. doi: 10.1038/s41591-022-02178-3. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928817 Free PMC article.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Le Gouill S, et al. Among authors: panizo c. Haematologica. 2024 Jan 1;109(1):343-350. doi: 10.3324/haematol.2022.282469. Haematologica. 2024. PMID: 37470152 Free PMC article. No abstract available.
Update on posttransplant lymphoproliferative disease.
Martin-Moreno PL, Panizo C. Martin-Moreno PL, et al. Among authors: panizo c. Curr Opin Nephrol Hypertens. 2018 Nov;27(6):440-444. doi: 10.1097/MNH.0000000000000457. Curr Opin Nephrol Hypertens. 2018. PMID: 30157079 Review.
Obinutuzumab in follicular lymphoma.
Martinez-Calle N, Figueroa-Mora R, Villar-Fernandez S, Marcos-Jubilar M, Panizo C. Martinez-Calle N, et al. Among authors: panizo c. Drugs Today (Barc). 2016 Dec;52(12):643-651. doi: 10.1358/dot.2016.52.12.2550578. Drugs Today (Barc). 2016. PMID: 28276536 Review.
Rituximab in dermatology.
España A, Ornilla E, Panizo C. España A, et al. Among authors: panizo c. Actas Dermosifiliogr. 2013 Jun;104(5):380-92. doi: 10.1016/j.adengl.2013.04.002. Epub 2013 May 10. Actas Dermosifiliogr. 2013. PMID: 23665436 Free article. Review. English, Spanish.
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.
Martín-Sánchez E, Tamariz-Amador LE, Guerrero C, Zherniakova A, Zabaleta A, Maia C, Blanco L, Alignani D, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Paiva B; Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) cooperative group. Martín-Sánchez E, et al. Among authors: panizo c. Blood Cancer J. 2024 Jul 10;14(1):111. doi: 10.1038/s41408-024-01089-5. Blood Cancer J. 2024. PMID: 38987557 Free PMC article.
117 results